Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Developments of mass spectrometry-based technologies for effective drug development linked with clinical proteomes.

In English

Författare

  • Noboru Nakayama
  • Yasuhiko Bando
  • Tetsuya Fukuda
  • Takeshi Kawamura
  • Haruhiko Nakamura
  • György Marko-Varga
  • Toshide Nishimura

Summary, in English

A strong demand in drug discovery and development today is to overcome "Big Gaps" encountered by differences in species and races, to accelerate effective developments in cost and time, and to meet medical needs. Moreover, drugs of various types have emerged which cover middle-size molecules and polymers rather than conventional small molecules. Upon those challenges, mass spectrometry (MS)-based technologies, which will be described in this paper, will play an increasingly important role, among which the liquid chromatography-tandem mass spectrometry (LC/MS/MS) platform will be powerful as rapid and molecule-based analysis more than ever. nanoPore Optical Interferometry (nPOI) newly introduced can detect even weak interactions in protein-protein and protein-compound, and can be connected directly to LC/MS/MS for identification of binding molecular species, which will be quite useful for affinity ranking and high-throughput interaction screening. Imaging MS provides the molecular information and spatial distribution of targeted molecules within a tissue specimen. MS-based clinical proteomics utilizing clinical specimens and empowered by advanced bioinformatics can attain both key protein-protein interaction (PPI) networks with major protein players responsible for functional mechanisms of a disease subtype. An integration of those MS-based technologies will deliver a seamless platform of drug development from molecules identified in human clinical specimens.

Publiceringsår

2016

Språk

Engelska

Sidor

3-11

Publikation/Tidskrift/Serie

Drug Metabolism and Pharmacokinetics

Volym

31

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

Japanese Society for the Study of Xenobiotics

Ämne

  • Pharmaceutical Sciences

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1347-4367